

Christine E. Staats

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4595726/publications.pdf>

Version: 2024-02-01

101
papers

5,131
citations

117453

34
h-index

91712

69
g-index

101
all docs

101
docs citations

101
times ranked

4596
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation. <i>Clinical Pharmacokinetics</i> , 2004, 43, 623-653.	1.6	708
2	Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2007, 46, 13-58.	1.6	481
3	Conditional Weighted Residuals (CWRES): A Model Diagnostic for the FOCE Method. <i>Pharmaceutical Research</i> , 2007, 24, 2187-2197.	1.7	282
4	Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I. <i>Clinical Pharmacokinetics</i> , 2010, 49, 141-175.	1.6	282
5	Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. <i>Intensive Care Medicine</i> , 2016, 42, 1535-1545.	3.9	244
6	Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II. <i>Clinical Pharmacokinetics</i> , 2010, 49, 207-221.	1.6	218
7	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 563-585.	0.7	184
8	Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. <i>Archives of Toxicology</i> , 2014, 88, 1351-1389.	1.9	166
9	Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 1905-1909.	0.4	131
10	Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 660-669.	2.3	127
11	Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 1050-1057.	1.3	124
12	Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. <i>Transplantation Reviews</i> , 2011, 25, 47-57.	1.2	116
13	Clinical Pharmacokinetics and Pharmacodynamics of Prednisolone and Prednisone in Solid Organ Transplantation. <i>Clinical Pharmacokinetics</i> , 2012, 51, 711-741.	1.6	92
14	Once- Versus Twice-Daily Tacrolimus. <i>Drugs</i> , 2011, 71, 1561-1577.	4.9	87
15	Predictors of new onset diabetes after renal transplantation. <i>Clinical Transplantation</i> , 2007, 21, 136-143.	0.8	82
16	Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2015, 54, 993-1025.	1.6	76
17	Population Pharmacokinetics of Tacrolimus in Adult Kidney Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 62-70.	1.0	70
18	Toward better outcomes with tacrolimus therapy: Population pharmacokinetics and individualized dosage prediction in adult liver transplantation. <i>Liver Transplantation</i> , 2003, 9, 130-137.	1.3	69

#	ARTICLE	IF	CITATIONS
19	Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1295-1335.	1.6	69
20	Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 509-523.	1.1	67
21	Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Patients with Autoimmune Disease. <i>Clinical Pharmacokinetics</i> , 2013, 52, 303-331.	1.6	65
22	Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 507-516.	0.8	62
23	Population Pharmacokinetics of Tobramycin in Patients With and Without Cystic Fibrosis. <i>Clinical Pharmacokinetics</i> , 2013, 52, 289-301.	1.6	59
24	Pharmacokinetic Considerations Relating to Tacrolimus Dosing in the Elderly. <i>Drugs and Aging</i> , 2005, 22, 541-557.	1.3	56
25	Pharmacogenetic influences on mycophenolate therapy. <i>Pharmacogenomics</i> , 2010, 11, 369-390.	0.6	47
26	Comparison of an ELISA and an LC/MS/MS Method for Measuring Tacrolimus Concentrations and Making Dosage Decisions in Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 607-615.	1.0	45
27	NR1I2 Polymorphisms Are Related to Tacrolimus Dose-Adjusted Exposure and BK Viremia in Adult Kidney Transplantation. <i>Transplantation</i> , 2012, 94, 1025-1032.	0.5	44
28	Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 207-223.	1.1	43
29	Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention. <i>Transplantation</i> , 2019, 103, 2012-2030.	0.5	43
30	Evaluation and Comparison of Simple Multiple Model, Richer Data Multiple Model, and Sequential Interacting Multiple Model (IMM) Bayesian Analyses of Gentamicin and Vancomycin Data Collected From Patients Undergoing Cardiothoracic Surgery. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 67-74.	1.0	41
31	Population Pharmacokinetics of Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Recipients: New Initial Dosage Suggestions and a Model-Based Dosage Adjustment Tool. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 457-466.	1.0	38
32	POPULATION PHARMACOKINETICS OF TACROLIMUS IN CHILDREN WHO RECEIVE CUT-DOWN OR FULL LIVER TRANSPLANTS. <i>Transplantation</i> , 2001, 72, 1056-1061.	0.5	38
33	Population Pharmacokinetics of Tacrolimus in Pediatric Liver Transplantation: Early Posttransplantation Clearance. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 663-672.	1.0	37
34	Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week. <i>Transplant International</i> , 2012, 25, 1182-1193.	0.8	35
35	Investigating barriers to immunosuppressant medication adherence in renal transplant patients. <i>Nephrology</i> , 2019, 24, 102-110.	0.7	35
36	Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 164-176.	1.1	34

#	ARTICLE	IF	CITATIONS
37	Therapeutic Monitoring of Mycophenolate in Transplantation: Is It Justified?. <i>Current Drug Metabolism</i> , 2009, 10, 179-187.	0.7	32
38	Maximum A Posteriori Bayesian Estimation of Mycophenolic Acid Area Under the Concentration-Time Curve: Is This Clinically Useful for Dosage Prediction Yet?. <i>Clinical Pharmacokinetics</i> , 2011, 50, 759-772.	1.6	31
39	Comparing Dosage Adjustment Methods for Once-Daily Tobramycin in Paediatric and Adolescent Patients with Cystic Fibrosis. <i>Clinical Pharmacokinetics</i> , 2015, 54, 409-421.	1.6	31
40	A pharmacodynamic investigation of tacrolimus in pediatric liver transplantation. <i>Liver Transplantation</i> , 2004, 10, 506-512.	1.3	28
41	An evaluation of the user-friendliness of Bayesian forecasting programs in a clinical setting. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2436-2441.	1.1	27
42	Evaluation of Limited Sampling Strategies for Mycophenolic Acid After Mycophenolate Mofetil Intake in Adult Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 723-733.	1.0	26
43	Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3407-3414.	1.4	26
44	Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw461.	1.3	26
45	Effects of Combinational CYP3A5 6986A>G Polymorphism in Graft Liver and Native Intestine on the Pharmacokinetics of Tacrolimus in Liver Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 442-447.	1.0	23
46	Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients. <i>Clinical Pharmacokinetics</i> , 2021, 60, 17-51.	1.6	23
47	Sampling Times for Monitoring Tacrolimus in Stable Adult Liver Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 593-599.	1.0	21
48	Evaluation of the Mycophenolic Acid Exposure Estimation Methods Used in the APOMYGERE, FDCC, and Optcept Trials. <i>Transplantation</i> , 2010, 90, 44-51.	0.5	21
49	BK Virus in Kidney Transplant Recipients: The Influence of Immunosuppression. <i>Journal of Transplantation</i> , 2011, 2011, 1-9.	0.3	21
50	Bayesian Forecasting and Prediction of Tacrolimus Concentrations in Pediatric Liver and Adult Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 158-166.	1.0	19
51	A Population Pharmacokinetic Model of Gentamicin in Pediatric Oncology Patients To Facilitate Personalized Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	17
52	Evaluation of limited sampling strategies for total and free prednisolone in adult kidney transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 1243-1252.	0.8	16
53	A limited sampling strategy for the simultaneous estimation of tacrolimus, mycophenolic acid and unbound prednisolone exposure in adult kidney transplant recipients. <i>Nephrology</i> , 2012, 17, 294-299.	0.7	16
54	Usage and monitoring of intravenous tobramycin in cystic fibrosis in Australia and the UK. <i>Journal of Pharmacy Practice and Research</i> , 2016, 46, 15-21.	0.5	15

#	ARTICLE	IF	CITATIONS
55	Quizzing for success: Evaluation of the impact of feedback quizzes on the experiences and academic performance of undergraduate students in two clinical pharmacokinetics courses. <i>Currents in Pharmacy Teaching and Learning</i> , 2019, 11, 742-749.	0.4	15
56	Characterizing the pharmacokinetics and pharmacodynamics of immunosuppressant medicines and patient outcomes in elderly renal transplant patients. <i>Translational Andrology and Urology</i> , 2019, 8, S198-S213.	0.6	15
57	How Accurate and Precise Are Limited Sampling Strategies in Estimating Exposure to Mycophenolic Acid in People with Autoimmune Disease?. <i>Clinical Pharmacokinetics</i> , 2014, 53, 227-245.	1.6	14
58	Ester prodrugs of a potent analgesic, morphine-6-sulfate: syntheses, spectroscopic and physicochemical properties. <i>International Journal of Pharmaceutics</i> , 1998, 163, 177-190.	2.6	13
59	Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 597-605.	0.8	13
60	Review: Pharmacodynamic monitoring of immunosuppression in kidney transplantation. <i>Nephrology</i> , 2010, 15, 522-532.	0.7	13
61	Multinational Evaluation of Mycophenolic Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus Utilization. <i>Annals of Transplantation</i> , 2016, 21, 1-11.	0.5	13
62	Exposureâ€“effect relationship of mycophenolic acid and prednisolone in adult patients with lupus nephritis. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1064-1075.	1.1	12
63	Kidney transplant recipientâ€™s perceptions of blood testing through microsampling and venepuncture. <i>Bioanalysis</i> , 2020, 12, 873-881.	0.6	12
64	Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 206-214.	1.4	11
65	Gentamicin Pharmacokinetics and Monitoring in Pediatric Patients with Febrile Neutropenia. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 693-698.	1.0	10
66	Comparison of methods to estimate glomerular filtration rate in paediatric oncology patients. <i>Journal of Paediatrics and Child Health</i> , 2018, 54, 141-147.	0.4	10
67	Investigation of the Association Between Total and Free Plasma and Saliva Mycophenolic Acid Concentrations Following Administration of Enteric-Coated Mycophenolate Sodium in Adult Kidney Transplant Recipients. <i>Clinical Drug Investigation</i> , 2019, 39, 1175-1184.	1.1	10
68	Oral bioavailability and pharmacokinetics of esculetin following intravenous and oral administration in rats. <i>Xenobiotica</i> , 2021, 51, 811-817.	0.5	10
69	Genetics and nonmelanoma skin cancer in kidney transplant recipients. <i>Pharmacogenomics</i> , 2015, 16, 161-172.	0.6	9
70	Is Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Justifiable for Gastrointestinal Quality of Life?. <i>Drugs in R and D</i> , 2018, 18, 271-282.	1.1	9
71	Relationships of tacrolimus pharmacokinetic measures and adverse outcomes in stable adult liver transplant recipients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2006, 31, 17-25.	0.7	8
72	Antimicrobial stewardship in paediatric oncology: Impact on optimising gentamicin use in febrile neutropenia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26810.	0.8	8

#	ARTICLE	IF	CITATIONS
73	Prescription Opioid Fatalities: Examining Why the Healer Could be the Culprit. <i>Drug Safety</i> , 2018, 41, 1023-1033.	1.4	8
74	Development of Improved Dosing Regimens for Mycophenolate Mofetil Based on Population Pharmacokinetic Analyses in Adults with Lupus Nephritis. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 993-1004.	0.6	8
75	Gentamicin Pharmacokinetics and Monitoring in Pediatric Febrile Neutropenic Patients. <i>Therapeutic Drug Monitoring</i> , 2016, , 1.	1.0	8
76	Identifying Drug-Related Readmissions Is There a Better Way of Assessing the Contribution of Adverse Medication Events?. <i>Journal of Pharmacy Practice and Research</i> , 2000, 30, 47-53.	0.2	7
77	Evaluation of Multiple Linear Regression-Based Limited Sampling Strategies for Enteric-Coated Mycophenolate Sodium in Adult Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 195-201.	1.0	7
78	Comparison of the Influence of Cyclosporine and Tacrolimus on the Pharmacokinetics of Prednisolone in Adult Male Kidney Transplant Recipients. <i>Clinical Drug Investigation</i> , 2014, 34, 183-188.	1.1	6
79	Exploratory Study of Total and Free Prednisolone Plasma Exposure and Cushingoid Appearance, Quality of Life and Biochemical Toxicity in Adult Male Kidney Transplant Recipients. <i>Clinical Drug Investigation</i> , 2015, 35, 743-750.	1.1	6
80	Population pharmacokinetic model for once-daily intravenous busulfan in pediatric subjects describing time^{-1} -associated clearance. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 1002-1017.	1.3	6
81	Sirolimus Increases T-Cell Abundance in the Sun Exposed Skin of Kidney Transplant Recipients. <i>Transplantation Direct</i> , 2017, 3, e171.	0.8	5
82	Evaluation of Bayesian Forecasting Methods for Prediction of Tacrolimus Exposure Using Samples Taken on Two Occasions in Adult Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 238-246.	1.0	5
83	Safety evaluation of oral calcitonin-gene-related peptide receptor antagonists in patients with acute migraine: a systematic review and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 1365-1376.	0.8	5
84	Expression of Bcl-xL and Mcl-1 in the Nonmelanoma Skin Cancers of Renal Transplant Recipients. <i>American Journal of Clinical Pathology</i> , 2015, 143, 514-526.	0.4	4
85	Balancing Antibacterial Efficacy and Reduction in Renal Function to Optimise Initial Gentamicin Dosing in Paediatric Oncology Patients. <i>AAPS Journal</i> , 2018, 20, 14.	2.2	4
86	Pharmacokinetic and Pharmacodynamic Considerations in Relation to Calcineurin Usage in Elderly Kidney Transplant Recipients. <i>Frontiers in Pharmacology</i> , 2021, 12, 635165.	1.6	4
87	Patterns in use and costs of conventional and biologic disease-modifying anti-rheumatic drugs in Australia. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 907-912.	0.4	4
88	Editorial: Therapeutic Drug Monitoring in Solid Organ Transplantation. <i>Frontiers in Pharmacology</i> , 2021, 12, 815117.	1.6	4
89	A comparison of mycophenolate use in Australia and Northern Europe, and the impact on the pharmaceutical benefits scheme. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 386-392.	0.9	3
90	A Differential Impact of Mycophenolic Acid, Prednisolone, and Tacrolimus Exposure on sCD30 Levels in Adult Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 240-245.	1.0	3

#	ARTICLE	IF	CITATIONS
91	Tacrolimus pharmacokinetics after kidney transplantation – Influence of changes in haematocrit and steroid dose. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1475-1476.	1.1	3
92	Pharmacometrics in Australasia – Twenty Years of Population Approach Group of Australia and New Zealand. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 701-704.	1.3	3
93	Comparison of free plasma versus saliva mycophenolic acid exposure following mycophenolate mofetil administration in adult kidney transplant recipients. <i>Clinical Biochemistry</i> , 2022, 100, 78-81.	0.8	3
94	Prednisolone Concentrations in Plasma (Total and Unbound) and Saliva of Adult Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 755-760.	1.0	2
95	Tacrolimus in Patients with Rheumatoid Arthritis. <i>Drugs</i> , 2005, 65, 1002-1003.	4.9	1
96	Pharmacokinetics of eperisone following oral administration in healthy Korean volunteers. <i>Biopharmaceutics and Drug Disposition</i> , 2021, 42, 94-102.	1.1	1
97	Patterns in use and costs of subsidising 5-aminosalicylic acid compounds and biologic agents in the treatment of inflammatory bowel disease in Australia. <i>Digestive and Liver Disease</i> , 2018, 50, 314-317.	0.4	0
98	Gender differences and dose proportionality in the toxicokinetics of udenafil and its active metabolite following oral administration in rodents. <i>Toxicology and Applied Pharmacology</i> , 2021, 410, 115339.	1.3	0
99	Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. <i>Xenobiotica</i> , 2021, 51, 194-201.	0.5	0
100	Evaluating the utilisation and expenditure patterns of erythropoietin stimulating agents and immunosuppressants in Australian chronic kidney disease patients. <i>Journal of Pharmaceutical Health Services Research</i> , 2021, 12, 350-356.	0.3	0
101	Immunosuppressant prescribing patterns in elderly kidney transplant recipients using registry data from Australia and New Zealand. <i>Journal of Pharmacy Practice and Research</i> , 0, , .	0.5	0